Actively Recruiting
Evaluation of Diagnostic Performances of 18F-FDOPA PET KInetics
Led by Central Hospital, Nancy, France · Updated on 2024-09-19
88
Participants Needed
1
Research Sites
176 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
the investigators hypothesise that 18F-FDOPA PET kinetic parameters are good biomarkers to characterise suspected LGG brain lesions that exhibit no contrast on MRI, for identifying aggressive lesions. These parameters could constitute diagnostic biomarkers for this indication. This new diagnostic tool could enhance patient care in the short term in an evolving pathology affecting socially active subjects with a poor prognosis
CONDITIONS
Official Title
Evaluation of Diagnostic Performances of 18F-FDOPA PET KInetics
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 75 years old
- WHO general condition 642
- Identification of a unifocal brain tumour at the initial diagnosis with no contrast in the MRI and suspected to be a LGG, with biopsy/surgery envisaged within 6 months of the PET scan
- MRI performed a maximum of 3 weeks before inclusion and comprising the conventional morphological sequences (T1, T1 sequences with injection of contrast agent and T2 FLAIR)
- Subject affiliated to or beneficiary of a social security plan
- Subject having received complete information on the organisation of the research and having signed the informed consent form.
You will not qualify if you...
- Multifocal brain lesions
- Contraindication to 18F-FDOPA PET
- Pregnant, parturient women or nursing mothers under Article L1121-5
- Women of childbearing age who do not have effective contraception under Article L1121-5
- Monitoring not possible
- Persons deprived of their liberty by a judicial or administrative decision under Article 1121-8, persons undergoing psychiatric treatment under Articles L. 3212-1 and L. 3213-1
- Patients cannot simultaneously participate in an interventional research trial for the duration of the KING study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
CHRU Nancy
Vandœuvre-lès-Nancy, France, 54511
Actively Recruiting
Research Team
V
VERONIQUE ROCH, MSc
CONTACT
A
ANTOINE VERGER, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here